Golcadomide and rituximab before CAR T for lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of two medications (golcadomide and rituximab) as a short-term treatment to shrink lymphoma before you receive CAR T-cell therapy. The goal is to make the CAR T treatment more effective for people whose lymphoma has come back or hasn't responded to previous treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older
- You must have one of the listed types of aggressive B-cell lymphoma that has come back or not responded to 1 or 2 prior treatments
- You must have a tumor that is at least 1.5 cm on a PET-CT scan
- Your doctor must think you are a candidate for CAR T-cell therapy
- You must have adequate kidney, liver, and blood cell counts (tests will be done)
- You must agree to use birth control if there is any chance of pregnancy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, golcadomide, given after CAR T-cell therapy to prevent relapse in people with aggressive large B-cell lymphoma who are at high risk. If you've had or are about to receive CAR T-cells, this study may help keep your lymphoma in remission.
This trial studies a lab-made immune cell treatment (CAR-T) for adults who have HIV and aggressive B-cell non-Hodgkin lymphoma that has come back or did not respond to prior treatment. It aims to see if the treatment can control the lymphoma safely in this specific group.
This Phase 2 study tests whether adding or switching drug treatments after CAR T-cell therapy can improve outcomes for people with certain aggressive lymphomas that have come back or did not respond. It mainly looks at who remains disease-stable/partly improved after CAR T and what treatment approach works best next.
This trial tests combining an experimental pill (CC-99282) with the immunotherapy drug rituximab for people with B-cell non-Hodgkin's lymphoma whose cancer did not fully respond to CAR-T cell therapy. The goal is to improve results after CAR-T.
This trial tests whether adding low-dose total body radiation before standard CAR-T cell therapy (Kymriah) helps people with relapsed or refractory large B-cell lymphoma. It aims to improve the effectiveness of the CAR-T cells.
This trial tests a new combination approach for people whose aggressive B-cell lymphoma has come back or not responded to treatment. It uses a bispecific antibody (a type of drug that helps immune cells attack cancer cells) followed by CAR-T cell therapy (reprogramming your own immune cells to find and kill cancer), sometimes with a stem cell transplant.
Hear when a new Recurrent Grade 3b Follicular Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.